发明名称 |
Pharmaceutical compositions with resistance to soluble CEA |
摘要 |
Abstract The present invention relates to pharmaceutical compositions for the treatment of an 5 epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the 10 production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed. 273985_1 (GHMatter) P78101 AU 1 |
申请公布号 |
AU2011204778(A1) |
申请公布日期 |
2011.08.04 |
申请号 |
AU20110204778 |
申请日期 |
2011.07.14 |
申请人 |
MICROMET AG |
发明人 |
LUTTERBUSE, RALF;MAYER, PETRA;SCHALLER, EVELYNE;RAU, DORIS;MANGOLD, SUSANNE;KUFER, PETER;MURR, ALEXANDER;WISSINGER, MONIKA;RAUM, TOBIAS |
分类号 |
C07K16/24;A61K39/395;C07K16/30 |
主分类号 |
C07K16/24 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|